Sign In
Buy IVA
$4.04
-0.0500 (-1.22%)
At Close: Jun 03, 2026
Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024
04:00pm, Wednesday, 22'nd May 2024
Daix (France), Long Island City (New York, United States), May 22, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral sm
Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update
04:00pm, Tuesday, 21'st May 2024
Daix (France), Long Island City (New York, United States), May 21, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the de
Daix (France), Long Island City (New York, United States), May 16, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the de
Daix (France), Long Island City (New York, United States), May 13, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral sm
Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F
04:00pm, Wednesday, 03'rd Apr 2024
Daix (France), Long Island City (New York, United States), April 3, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the d
Inventiva S.A. (IVA) Q4 2023 Earnings Call Transcript
11:27am, Thursday, 28'th Mar 2024
Inventiva S.A. (IVA) Q4 2023 Earnings Call Transcript
Inventiva announces the nomination of Andre Turenne as Director
03:00am, Thursday, 28'th Mar 2024
Daix (France), Long Island City (New York, United States), March 28, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the
Inventiva reports its 2023 full-year results
04:00pm, Wednesday, 27'th Mar 2024
Revenues at €17.5 million for the full year of 2023 up 43.4% compared to €12.2 million for 2022 Cash and cash equivalents at €26.9 million, short-term deposits at €0.01 million1, and long-te
Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results
04:00pm, Friday, 22'nd Mar 2024
Daix (France), Long Island City (New York, United States), March 22, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral
Daix (France), Long Island City (New York, United States), March 18, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral
Daix (France), Long Island City (New York, United States), March 13, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the
Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed
04:00pm, Thursday, 07'th Mar 2024
Daix (France), Long Island City (New York, United States), March 7, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the d
Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause
04:50pm, Thursday, 22'nd Feb 2024
Enrollment pause in phase III NATiV3 study, using lanifibranor for the treatment of patients with NASH, only expected to last 4 to 6 weeks; Trial to continue on with protocol amendments. Publication o
Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3
04:35pm, Thursday, 15'th Feb 2024
Daix (France), Long Island City (New York, United States), February 15, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on t
Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux
04:15pm, Wednesday, 24'th Jan 2024
Daix (France), Long Island City (New York, United States), January 24, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on th
